Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 52
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Br J Cancer ; 109(10): 2523-32, 2013 Nov 12.
Artigo em Inglês | MEDLINE | ID: mdl-24149176

RESUMO

BACKGROUND: Allogeneic haematopoietic stem cell transplantation (allo-SCT) may provide donor cytotoxic T cell-/NK cell-mediated disease control in patients with rhabdomyosarcoma (RMS). However, little is known about the prevalence of graft-vs-RMS effects and only a few case experiences have been reported. METHODS: We evaluated allo-SCT outcomes of 30 European Group for Blood and Marrow Transplantation (EBMT)-registered patients with advanced RMS regarding toxicity, progression-free survival (PFS) and overall survival (OS) after allo-SCT. Twenty patients were conditioned with reduced intensity and ten with high-dose chemotherapy. Twenty-three patients were transplanted with HLA-matched and seven with HLA-mismatched grafts. Three patients additionally received donor lymphocyte infusions (DLIs). Median follow-up was 9 months. RESULTS: Three-year OS was 20% (s.e.±8%) with a median survival time of 12 months. Cumulative risk of progression was 67% (s.e.±10%) and 11% (s.e.±6%) for death of complications. Thirteen patients developed acute graft-vs-host disease (GvHD) and five developed chronic GvHD. Eighteen patients died of disease and four of complications. Eight patients survived in complete remission (CR) (median: 44 months). No patients with residual disease before allo-SCT were converted to CR. CONCLUSION: The use of allo-SCT in patients with advanced RMS is currently experimental. In a subset of patients, it may constitute a valuable approach for consolidating CR, but this needs to be validated in prospective trials.


Assuntos
Transplante de Células-Tronco Hematopoéticas/métodos , Rabdomiossarcoma/cirurgia , Adolescente , Adulto , Criança , Pré-Escolar , Progressão da Doença , Feminino , Doença Enxerto-Hospedeiro/etiologia , Doença Enxerto-Hospedeiro/mortalidade , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Humanos , Masculino , Recidiva Local de Neoplasia/epidemiologia , Recidiva Local de Neoplasia/mortalidade , Estudos Retrospectivos , Rabdomiossarcoma/mortalidade , Transplante Homólogo , Adulto Jovem
2.
Klin Padiatr ; 224(6): 353-8, 2012 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22821288

RESUMO

BACKGROUND: Risk stratification criteria for patients with Ewing's sarcoma family of tumors (ESFT) are still limited. We hypothesized divergent human leukocyte antigen (HLA) patterns in ESFT patients and compared HLA-A, -B and -DR phenotype frequencies of patients with advanced ESFT with those of healthy controls. PATIENTS: HLA types of all German Caucasian patients with advanced ESFT and available HLA-A, -B and -DR data registered in the European Group for Blood and Marrow Transplantation, Paediatric Registry for Stem Cell Transplantation and the MetaEICESS data bases (study group, n=30) were retrospectively compared with HLA types of healthy German stem cell donors (control group, n=8 862 for single HLA frequencies and n=8 839 for allele combinations). Study group patients had been immuno-typed due to eligibility for allogeneic stem cell transplantation for high risk of treatment failure, and thus constituted a selected subgroup of ESFT patients. RESULTS: After Bonferroni correction for multiple testing (PC), phenotype frequencies of HLA-A24 remained significantly higher in the study group compared to controls (PC<0.05). Furthermore, several HLA combinations were significantly more frequent in the study group compared to controls (all PC<0.05). CONCLUSION: We report an increased incidence of circumscribed HLA patterns in German Caucasians with advanced ESFT. The possible clinical significance of this observation has to be re-assessed in prospective trials comprising larger ESFT patient numbers of all risk groups.


Assuntos
Doadores de Sangue , Transplante de Medula Óssea , Neoplasias Ósseas/genética , Neoplasias Ósseas/terapia , Antígenos HLA-A/genética , Antígenos HLA-B/genética , Antígenos HLA-DR/genética , Transplante de Células-Tronco Hematopoéticas , Sarcoma de Ewing/genética , Sarcoma de Ewing/terapia , Doadores de Tecidos , Adolescente , Adulto , Neoplasias Ósseas/patologia , Criança , Progressão da Doença , Feminino , Frequência do Gene , Genética Populacional , Alemanha , Humanos , Masculino , Recidiva Local de Neoplasia/genética , Recidiva Local de Neoplasia/patologia , Recidiva Local de Neoplasia/terapia , Estadiamento de Neoplasias , Estudos Retrospectivos , Sarcoma de Ewing/patologia , Adulto Jovem
3.
Br J Cancer ; 104(6): 948-56, 2011 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-21407224

RESUMO

BACKGROUND: The development of a successful immunotherapy is hampered by an ineffective T-cell repertoire against tumour antigens and the inability of the patient's immune system to overcome tolerance-inducing mechanisms. Here, we test the specific recognition and lytical potential of allo-restricted CD8(+) T cells against Ewing tumour (ET) associated antigens Enhancer of Zeste, Drosophila Homolog 2 (EZH2), and Chondromodulin-I (CHM1) identified through previous microarray analysis. METHODS: Following repetitive CHM1(319) (VIMPCSWWV) and EZH2(666) (YMCSFLFNL) peptide-driven stimulations with HLA-A 0201(+) dendritic cells (DC), allo-restricted HLA-A 0201(-) CD8(+) T cells were stained with HLA-A 0201/peptide multimers, sorted and expanded by limiting dilution. RESULTS: Expanded T cells specifically recognised peptide-pulsed target cells or antigen-transfected cells in the context of HLA-A 0201 and killed HLA-A 0201(+) ET lines expressing the antigen while HLA-A 0201(-) ET lines were not affected. Furthermore, adoptively transferred T cells caused significant ET growth delay in Rag2(-/-)γ(C)(-/-) mice. Within this context, we identified the CHM1(319) peptide as a new candidate target antigen for ET immunotherapy. CONCLUSION: These results clearly identify the ET-derived antigens, EZH2(666) and CHM1(319), as suitable targets for protective allo-restricted human CD8(+) T-cell responses against non-immunogenic ET and may benefit new therapeutic strategies in ET patients treated with allogeneic stem cell transplantation.


Assuntos
Antígenos de Neoplasias/imunologia , Neoplasias Ósseas/patologia , Isoantígenos/imunologia , Sarcoma de Ewing/patologia , Linfócitos T Citotóxicos/imunologia , Animais , Antígenos de Neoplasias/metabolismo , Neoplasias Ósseas/imunologia , Linhagem Celular Tumoral , Proliferação de Células , Células Cultivadas , Citotoxicidade Imunológica/imunologia , Proteínas de Ligação a DNA/genética , Regulação para Baixo , Humanos , Imunoterapia Adotiva , Isoantígenos/metabolismo , Células K562 , Camundongos , Camundongos Knockout , Sarcoma de Ewing/imunologia , Especificidade do Receptor de Antígeno de Linfócitos T/imunologia , Linfócitos T Citotóxicos/metabolismo
4.
Ann Oncol ; 22(7): 1614-1621, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21245159

RESUMO

BACKGROUND: Outcomes of Ewing tumor (ET) patients treated with allogeneic stem cell transplantation (allo-SCT) were compared regarding the use of reduced-intensity conditioning (RIC) and high-intensity conditioning (HIC) regimens as well as human leukocyte antigen (HLA)-matched and HLA-mismatched grafts. PATIENTS AND METHODS: We retrospectively analyzed data of 87 ET patients from the European Group for Blood and Marrow Transplantation, Pediatric Registry for Stem Cell Transplantations, Asia Pacific Blood and Marrow Transplantation and MetaEICESS registries treated with allo-SCT. Fifty patients received RIC (group A) and 37 patients received HIC (group B). Twenty-four patients received HLA-mismatched grafts and 63 received HLA-matched grafts. RESULTS: Median overall survival was 7.9 months [±1.24, 95% confidence interval (CI) 5.44-10.31] for group A and 4.4 months (±1.06, 95% CI 2.29-6.43) for group B patients (P = 1.3). Death of complications (DOC) occurred in 4 of 50 (0.08) and death of disease (DOD) in 33 of 50 (0.66) group A and in 16 of 37 (0.43) and 17 of 37 (0.46) group B patients, respectively. DOC incidence was decreased (P < 0.01) and DOD/relapse increased (P < 0.01) in group A compared with group B. HLA mismatch was not generally associated with graft-versus-Ewing tumor effect (GvETE). CONCLUSIONS: There was no improvement of survival with RIC compared with HIC due to increased DOD/relapse incidence after RIC despite less DOC incidence. This implicates general absence of a clinically relevant GvETE with current protocols.


Assuntos
Neoplasias Ósseas/mortalidade , Neoplasias Ósseas/terapia , Doença Enxerto-Hospedeiro/terapia , Sarcoma de Ewing/mortalidade , Sarcoma de Ewing/terapia , Transplante de Células-Tronco , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Taxa de Sobrevida , Condicionamento Pré-Transplante , Transplante Homólogo , Resultado do Tratamento , Adulto Jovem
5.
Bone Marrow Transplant ; 56(7): 1550-1557, 2021 07.
Artigo em Inglês | MEDLINE | ID: mdl-33514918

RESUMO

Patients with advanced Ewing sarcoma (AES) carry a poor prognosis. Retrospectively, we analyzed 66 AES patients treated with allogeneic stem cell transplantation (allo-SCT) receiving HLA-mismatched (group A, n = 39) versus HLA-matched grafts (group B, n = 27). Median age at diagnosis was 13 years, and 15 years (range 3-49 years) at allo-SCT. The two groups did not differ statistically in distribution of gender, age, remission status/number of relapses at allo-SCT, or risk stratum. 9/39 (23%) group A versus 2/27 (7%) group B patients developed severe acute graft versus host disease (GvHD). Of patients alive at day 100, 7/34 (21%) group A versus 9/19 (47%) group B patients had developed chronic GvHD. In group A, 33/39 (85%) versus 20/27 (74%) group B patients died of disease and 1/39 (3%) versus 1/27 (4%) patients died of complications, respectively. Altogether 12/66 (18%) patients survived in CR. Median EFS 24 months after allo-SCT was 20% in both groups, median OS was 27% (group A) versus 17% (group B), respectively. There was no difference in EFS and OS in AES patients transplanted with HLA-mismatched versus HLA-matched graft in univariate and multivariate analyses. In this analysis, CR at allo-SCT is a condition for survival (p < 0.02).


Assuntos
Doença Enxerto-Hospedeiro , Transplante de Células-Tronco Hematopoéticas , Sarcoma de Ewing , Adolescente , Adulto , Criança , Pré-Escolar , Humanos , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , Estudos Retrospectivos , Sarcoma de Ewing/terapia , Condicionamento Pré-Transplante , Adulto Jovem
6.
Mol Vis ; 14: 1437-45, 2008 Aug 04.
Artigo em Inglês | MEDLINE | ID: mdl-18682810

RESUMO

PURPOSE: To analyze protein patterns in the aqueous humor of glaucoma patients in comparison to control subject using two different methods. METHODS: Aqueous humor was collected from 52 patients with primary open-angle glaucoma (POAG) and from 55 control subjects (CO). Twenty-two POAG samples and 24 CO samples were used for protein profiling through surface enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS) ProteinChip arrays. The data were analyzed by multivariate statistical methods and artificial neural networks. One highly significant biomarker was identified through matrix assisted laser desorption/ionisation time of flight-mass spectrometry (MALDI-TOF). Thirty samples from patients with POAG and 31 control samples were analyzed through two-dimensional electrophoresis. Subsequently, the protein spots of all gels were detected, and the two groups were compared. One spot group exhibiting clear differential abundance was identified by mass spectrometry (electrospray ionization mass spectrometry). RESULTS: In the samples analyzed by SELDI-TOF-MS, about 250 protein peaks could be consistently clustered in both groups. The analyses revealed eight biomarkers, which discriminated glaucoma from non-glaucoma controls with a sensitivity of 90% and a specificity of 87%. These biomarkers were purified further, and one marker, which was upregulated in glaucoma patients (p=0.006), was identified as transthyretin. The upregulation of transthyretin in POAG patients was also confirmed by enzyme linked immunosorbent assay (ELISA; p=0.03). In all samples analyzed by two-dimensional electrophoresis, complex protein patterns were detected in a total of 177 spot groups. The aqueous humor of all glaucoma patients revealed some regions that were clearly different from the controls. Several spots were significantly increased in the aqueous humor of glaucoma patients. One of the proteins that is highly abundant in the aqueous of glaucoma patients was identified as transthyretin. CONCLUSIONS: The aqueous humor of glaucoma patients revealed characteristic differences in protein/peptide profiles from control patients using two different analytical methods, SELDI-TOF-MS and two-dimensional electrophoresis. Interestingly, we could detect elevated transthyretin concentrations in glaucoma samples. Transthyretin might play a role in the onset of glaucoma since it has been shown to form amyloid deposits. These particles could cause outflow obstructions thereby increasing intraocular pressure as a possible onset mechanism.


Assuntos
Humor Aquoso/química , Proteínas do Olho/análise , Glaucoma de Ângulo Aberto/metabolismo , Pré-Albumina/análise , Idoso , Estudos de Casos e Controles , Eletroforese em Gel Bidimensional , Ensaio de Imunoadsorção Enzimática , Proteínas do Olho/química , Humanos , Pré-Albumina/química , Curva ROC , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz
8.
Exp Hematol ; 25(7): 601-7, 1997 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-9216735

RESUMO

The proteindisulfide isomerase (PDI), a multifunctional cytoplasmic enzyme with additional chaperone activity, has been shown recently, using monoclonal antibodies, to be located on the membrane of mature human B lymphocytes and B cell chronic lymphocytic leukemia (B-CLL) cells. Here, evidence is presented that this antigen exhibits catalytic activity as measured by the reductive degradation of insulin (release of A chain molecules) on intact B cells in patients suffering from B-CLL, as well as on JVM 13 cells (B-CLL cell line). More than 98% of these cells exhibited PDI activity which could be inhibited by bacitracin and also by monoclonal and polyclonal antibodies to PDI. Interestingly, surface PDI expression was strongly correlated in our study with protein-bound membrane SH groups. These surface protein thiols were specifically determined by using low concentrations of the chloromethyl-derivative based fluorescent probe 5-(and6)-(((4-chloromethyl)-benzoyl)amino)-tetramethyl-rhodamine (CMTMR) at low temperature in the presence of sodium azide in flow cytometry. The highest PDI and SH expression was found on B lymphocytes, particularly B-CLL cells. The mean fluorescence intensity (MFI) of CMTMR-positive B cells in the B-CLL line was up to 10-fold higher than that of controls, indicating a strong elevation of cell membrane-located protein thiols on malignant B cells. The link between PDI and SH expression on cell surfaces points to a functional interaction between the two. Treatment with bacitracin resulted in a strong inhibition of PDI and a dramatic increase in surface protein thiol expression of B-CLL cells. Similar effects could be observed by cell treatment with anti-PDI antibodies, indicating that this enzyme system plays a crucial role in the regulation of protein-bound SH groups. Interestingly, artificially induced protein thiol expression led to significantly higher cellular resistance to the cytostatic drugs chlorambucil, vinblastin, and cisplatin in vitro as measured by cell growth. These data suggest for the first time a regulatory effect of PDI on the surface protein thiol status of B cells. The increased expression of PDI may play a crucial role in SH-mediated protection and drug resistance in malignant B lymphocytes.


Assuntos
Linfócitos B/metabolismo , Isomerases/metabolismo , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Compostos de Sulfidrila/metabolismo , Bacitracina/farmacologia , Clorambucila/farmacologia , Cisplatino/farmacologia , Citarabina/farmacologia , Resistencia a Medicamentos Antineoplásicos , Humanos , Isomerases/antagonistas & inibidores , Leucemia Linfocítica Crônica de Células B/enzimologia , Isomerases de Dissulfetos de Proteínas , Propriedades de Superfície , Células Tumorais Cultivadas , Vimblastina/farmacologia
9.
Free Radic Biol Med ; 29(11): 1160-5, 2000 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11121724

RESUMO

In increasing numbers of pulmonary diseases an association with a loss of intracellular thiols, mainly glutathione, is postulated. Therefore, the quantitative measurement of thiols within different viable cells is a possible metabolic parameter for cellular function and defense capacity of all pulmonary immune cells including alveolar macrophages (AM), that are highly compromised by oxidative stress. In this study the cellular thiol content was determined using fluorochrom conjugated chloromethyl derivatives (5-chloromethylfluorescein diacetate, CMFDA) in flow cytometry. The procedure was evaluated in vitro using biochemical techniques for glutathione quantification. Based on this approach, AM obtained from bronchoalveolar lavage (BAL) of smokers and patients with chronic obstructive pulmonary disease (COPD) showed a significant thiol deficiency compared to a nonsmoker/non-COPD group. The cellular thiol expression of AM from smokers and COPD patients reached only 50 and 53% of the control group. Lowest thiol concentrations (47% of control) were detected within the smoker(+)/COPD(+) group. This intracellular thiol deficiency significantly correlated with reduced lung function (FEV(1), PaO(2)). With regard to the tightly regulated thiol metabolism of immune cells, these results imply the onset of functional disturbances in thiol deficient AM. The determination of the cellular thiol content of AM, obtained from BAL by flow cytometry, presents a simple and reliable tool to monitor the effect of therapeutic measures focusing on the stabilization of the cellular thiol status.


Assuntos
Pneumopatias Obstrutivas/metabolismo , Macrófagos Alveolares/metabolismo , Fumar , Compostos de Sulfidrila/análise , Idoso , Líquido da Lavagem Broncoalveolar/citologia , Citometria de Fluxo , Fluoresceínas , Corantes Fluorescentes , Glutationa/análise , Humanos , Macrófagos Alveolares/química , Pessoa de Meia-Idade , Estresse Oxidativo
10.
Free Radic Res ; 34(2): 137-51, 2001 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11264891

RESUMO

During continuous ambulatory peritoneal dialysis (CAPD) the peritoneal immune cells, mainly macrophages, are highly compromised by multiple factors including oxidative stress, resulting in a loss of functional activity. One reason for the increase of inflammatory reactions could be an imbalance in the thiol-disulfide status. Here, the possible protective effects of the antioxidant flavonoid complex silymarin and its major component silibinin on the cellular thiol status were investigated. Peritoneal macrophages from dialysis fluid of 30 CAPD patients were treated with silymarin or silibinin up to 35 days. A time-dependent increase of intracellular thiols was observed with a nearly linear increment up to 2.5-fold after 96 hours, reaching a maximum of 3.5-fold after 20 days of culture. Surface-located thiols were also elevated. The stabilization of the cellular thiol status was followed by an improvement of phagocytosis and the degree of maturation as well as significant changes in the synthesis of IL-6 and IL-1ra. Furthermore, the treatment of peritoneal macrophages with flavonoids in combination with cysteine donors resulted in a shortened and more efficient time course of thiol normalization as well as in a further increased phagocytosis. In addition, GSH-depletion in thiol-deficient media simulating CAPD procedures led to intracellular thiol deficiency similar to the in vivo situation. It is concluded that treatment with milk thistle extracts silymarin and silibinin alone or, more effectively in combination with cysteine donors, provide a benefit for peritoneal macrophages of CAPD-patients due to a normalization and activation of the cellular thiol status followed by a restoration of specific functional capabilities.


Assuntos
Macrófagos Peritoneais/efeitos dos fármacos , Diálise Peritoneal Ambulatorial Contínua , Silimarina/farmacologia , Compostos de Sulfidrila/metabolismo , Acetilcisteína/farmacologia , Adulto , Idoso , Antígenos CD/biossíntese , Células Cultivadas/efeitos dos fármacos , Corantes , Cisteína/fisiologia , Feminino , Citometria de Fluxo , Fluoresceínas/análise , Regulação da Expressão Gênica/efeitos dos fármacos , Glutationa/fisiologia , Humanos , Proteína Antagonista do Receptor de Interleucina 1 , Interleucina-6/biossíntese , Interleucina-6/genética , Masculino , Pessoa de Meia-Idade , Estresse Oxidativo , Diálise Peritoneal Ambulatorial Contínua/efeitos adversos , Fagocitose/efeitos dos fármacos , Sialoglicoproteínas/biossíntese , Sialoglicoproteínas/genética
11.
Hybridoma ; 10(6): 651-7, 1991 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-1816070

RESUMO

The Protein disulphide-isomerase (PDI, EC 5.3.4.1, Thiol-proteindisulphide oxidoreductase, EC 1.8.4.2) is thought to regulate the sulfhydryl status of cells and to catalyze thiol/disulphide exchange reactions involved in the post-translational processing of disulphide containing secretory proteins. The aim of the present investigations was to study the possible function of this enzyme in differentiation of B lymphocytes and immunoglobulin synthesis. Non-adherent human mononuclear cells or purified T cells were cultured in presence and absence of Pokeweed mitogen over 3, 5 and 7 days. Monoclonal antibodies and a rabbit polyclonal antiserum specific for human liver PDI were produced to determine the concentration of PDI by an ELISA technique and cytoplasmic immunofluorescence. After PWM stimulation, both, the cellular content of PDI as well as that of immunoglobulin, particularly IgM, have been found to be induced in a time dependent manner with a 2-3 fold increase in comparison to unstimulated cells. The specific induction of PDI in human B lymphocytes was also confirmed in Western blotting. Our findings suggest that PDI plays a critical role in the final stages of B cell differentiation and immunoglobulin synthesis by activated B cells and plasma cells, respectively.


Assuntos
Linfócitos B/efeitos dos fármacos , Imunoglobulinas/biossíntese , Isomerases/biossíntese , Mitógenos de Phytolacca americana , Anticorpos Monoclonais/imunologia , Linfócitos B/metabolismo , Diferenciação Celular , Células Cultivadas , Indução Enzimática/efeitos dos fármacos , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Imunoglobulina M/biossíntese , Isomerases/imunologia , Ativação Linfocitária , Isomerases de Dissulfetos de Proteínas
12.
Urologe A ; 42(1): 104-12, 2003 Jan.
Artigo em Alemão | MEDLINE | ID: mdl-12577160

RESUMO

Today, the classical bacteria that cause venereal diseases, e.g. gonorrhea, syphilis, chancroid and inguinal granuloma, only account for a small proportion of all known sexually transmitted diseases (STDs). Other bacteria and viruses as well as yeasts, protozoa and epizoa must also be regarded as causative organisms of STD. Taken together, all sexually transmitted infections comprise more than 30 relevant STD pathogens. However, not all pathogens that can be sexually transmitted manifest diseases in the genitals and not all infections of the genitals are exclusively sexually transmitted. Concise information and tables summarising the diagnostic and therapeutic management of STDs in the field of urology allow a synoptic overview, and are in agreement with the recent international guidelines of other specialist areas. Special considerations (i.e. HIV infection, pregnancy, infants, allergy) and recommended regimens are presented.


Assuntos
Doenças dos Genitais Masculinos/diagnóstico , Infecções Sexualmente Transmissíveis/diagnóstico , Notificação de Doenças/legislação & jurisprudência , Feminino , Doenças dos Genitais Masculinos/terapia , Alemanha , Humanos , Recém-Nascido , Masculino , Gravidez , Infecções Sexualmente Transmissíveis/terapia , Sociedades Médicas
13.
Bone Marrow Transplant ; 45(3): 483-9, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19684633

RESUMO

We examined the role of total body magnetic resonance imaging (TB-MRI)-governed involved compartment irradiation (ICI) and high-dose chemotherapy (HDC), followed by stem cell rescue (SCR) in patients with high-risk Ewing tumors (ETs) with multiple primary bone metastases (high-risk ET-MBM). Eleven patients with high-risk ET-MBM receiving initial assessment of involved bones by TB-MRI were registered from 1995 to 2000 (group A). In all, 6 patients out of 11 had additional lung disease at initial diagnosis; all had multifocal bone disease with more than three bones involved. After systemic induction with etoposide, vincristine, adriamycin (doxorubicin), ifosfamide, and actinomycin D (EVAIA) or VAIA chemotherapy, ICI of all sites positive by TB-MRI was administered, followed by HDC and SCR. A second group matched for observation period and consisting of 26 patients with more than three involved bones at diagnosis was treated with the European Intergroup Cooperative Ewing Sarcoma Study-92 (EICESS-92) protocol (group B). These patients did not receive TB-MRI and consequently did not receive TB-MRI-governed ICI, or HDC and SCR. Survival in group A vs group B was 45 vs 8% at 5 years and 27 vs 8% at 10 years after diagnosis (log rank and Breslow: P<0.005). We conclude that TB-MRI-governed ICI followed by HDC and SCR in ET-MBM is feasible and warrants further evaluation in prospective studies.


Assuntos
Neoplasias Ósseas/terapia , Sarcoma de Ewing/terapia , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Neoplasias Ósseas/tratamento farmacológico , Neoplasias Ósseas/radioterapia , Neoplasias Ósseas/secundário , Criança , Protocolos Clínicos , Terapia Combinada , Feminino , Transplante de Células-Tronco Hematopoéticas , Humanos , Estimativa de Kaplan-Meier , Imageamento por Ressonância Magnética , Masculino , Sarcoma de Ewing/tratamento farmacológico , Sarcoma de Ewing/radioterapia , Sarcoma de Ewing/secundário , Irradiação Corporal Total/métodos , Adulto Jovem
14.
Vet Rec ; 106(2): 43, 1980 Jan 12.
Artigo em Inglês | MEDLINE | ID: mdl-7361401
16.
Z Urol Nephrol ; 73(4): 307-13, 1980 Apr.
Artigo em Alemão | MEDLINE | ID: mdl-7445786

RESUMO

In order to establish the actual recidivation rate, the patients with partial resections of the kidneys of the years 1965 to 1978 were examined. Of 120 patients treated 106 could be examined for the second time, at a mean time of secondary examination of 6.5 years. 24.5% of the patients had a recidivation at the time of the examination. The annual recidivation rate was calculated depending on the examination. It increases with the duration of the time of the after-examination. The comparison with the recidivation number after pyelolithotomy (26.7%) does not show an evident effect of the partial resection of the kidney on the frequency of recidivations. In the judgment, however, the selection of these patients for this operation technique is to be taken into consideration. The use of the coagulum pyelolithotomy has led to a more stringent indication for the partial resection of the kidney.


Assuntos
Cálculos Renais/cirurgia , Adolescente , Adulto , Idoso , Criança , Feminino , Seguimentos , Humanos , Masculino , Métodos , Pessoa de Meia-Idade , Recidiva
17.
Z Urol Nephrol ; 73(4): 267-77, 1980 Apr.
Artigo em Alemão | MEDLINE | ID: mdl-6160693

RESUMO

On principle every vesical tumour should be resected at first transurethrally. The TUTUR allows an exact establishment of the penetration depth of the tumour. The transurethral electro-resection gives representative tissue for the histological examination. For the majority of the superficially infiltrating tumours it represents the method of choice with curative aim. In the treatment of the progressed vesical carcinomas the TUTUR with palliative aim gives immense advantages. Using the developing paravesical inflammation wall the following secondary (and more) resection into the perivesical fatty tissue is possible. The intervention can be repeated at every time it is not mutilating does not cause any stoma problems or metabolic derangements as after discharge of the urine and may be suggested to patients in a general condition which forbids an open surgical intervention. The resection can improve the quality of the patient's life for a long time without great stress and thorough changes of the life habits of old people. However the resection treatment will be successful only then, when it will be performed by an experienced (in transurethral operations) operator with a technically good instrumentarium.


Assuntos
Carcinoma/cirurgia , Eletrocirurgia/métodos , Papiloma/cirurgia , Neoplasias da Bexiga Urinária/cirurgia , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Metástase Neoplásica , Cuidados Paliativos , Prognóstico
18.
Z Urol Nephrol ; 73(4): 297-301, 1980 Apr.
Artigo em Alemão | MEDLINE | ID: mdl-6160696

RESUMO

In the period from 1970 to 1978 24 patients after transvesical adenomectomy and 76 patients after TUR of the prostate gland underwent a secondary transurethral surgical intervention. Causes were residual adenomas, stenoses of the vesical neck and recidivations of the adenoma. Explanations are given for the differences in the course of the temporary coordination to the primary intervention. The preoperative situation concerning infections, problems of the operation technique and in the case of the TUR the qualification of the resectionists are mentioned. After the TUR as primary intervention clearly less carcinomas were proved in the electro-resectate in comparison to the transvesical adenomectomy.


Assuntos
Obstrução do Colo da Bexiga Urinária/cirurgia , Humanos , Masculino , Prostatectomia/efeitos adversos , Prostatectomia/métodos , Hiperplasia Prostática/cirurgia , Recidiva , Obstrução do Colo da Bexiga Urinária/etiologia
19.
Z Urol Nephrol ; 80(7): 401-7, 1987 Jul.
Artigo em Alemão | MEDLINE | ID: mdl-3660962

RESUMO

From 1975 to 1985 519 patients with urinary calculi were treated in the Urologic Clinic of the Berlin-Buch Hospitals. 57.6% of them were treated by lithotripsy and TUR-P, 14.8% by lithotripsy alone, 11.8% by stone removal and transvesical adenomectomy and 15.8% by suprapubic cystotomy only. The diagnosis of the four forms of therapy is described. The trend in the conception of treatment goes to the treatment of calculi transurethrally in combination with the simultaneous removal of the obstruction of the outflow from the urinary bladder. Since October 1985 the electrohydraulic lithotripsy has been used. Up to 1985 in 218 patients urinary calculi were crushed by means of the device Urat-1. In 190 patients (87.3%) the lithotripsy was carried out in combination with other therapeutic measures, in 153 (70.2%) a transurethral resection of the prostate gland and in 28 patients (12.9%) other transurethral interventions were performed. Postoperatively, in 7 patients complications occurred (3.2%), perforations of the urinary bladder were not seen. Taking into consideration the whole number of patients, it is reported on the advantages of the use of the electrohydraulic lithotripsy by means of the apparatus Urat-1 as an uncomplicated technique easily to be learned, which excellently may be combined with simultaneous transurethral interventions.


Assuntos
Litotripsia/métodos , Cálculos da Bexiga Urinária/terapia , Idoso , Terapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Obstrução do Colo da Bexiga Urinária/terapia
20.
Z Alternsforsch ; 33(4): 303-9, 1978.
Artigo em Alemão | MEDLINE | ID: mdl-84444

RESUMO

The people become elder in this time, everywhere. The number of patients with adenoma of the prostate is increasing. Most of them have other diseases, too. A retrospective study (2646 cases in 8 years, exactly specially analysed 469 cases from 1975/1976) was done, comparing the results of TUR and open surgery. Well known is the lower risk of TUR, the lower blood loss, the lower discomfort, the lower nursing in the postoperative period ect. There are not news in this study. But it is important, to recall some things, because it's more and more difficult, to classify an old man as an "inoperable case". Nobody knows, where he should stay. The family does not like him at home (his "dripping", his incontinence etc.) In the veterans house it's the same problem, and from the hospital he is removed, because he is an "inoperable case". The situation of this old man is very bad, because he feels there isn't a place for him and nobody likes him. Each man, also if it's the strongest one, will be broken psychically and physically after a short time. Concerning these aspects, must be enlarged the indication of removal the bladder neck obstruction per transurethral resection, more and more.


Assuntos
Prostatectomia/métodos , Hiperplasia Prostática/cirurgia , Cateterismo Urinário/métodos , Incontinência Urinária/terapia , Idoso , Cateteres de Demora , Eletrocoagulação , Humanos , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Hiperplasia Prostática/complicações , Uretra , Incontinência Urinária/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA